A Phase 3 interventional study of Dapagliflozin and Placebo for dapagliflozin in Type 1 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 137 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-05.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 — 2 open to participants now, 5 under way, 2 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 1.
Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 4 that started in 2015, is one of 7 in phase 3, and was the 4th registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:
St Vincent's Hospital Melbourne · Sites in Australia
Ages 24–85
Dasman Diabetes Institute · Sites in Kuwait, Qatar, Saudi Arabia
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 815 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 43 across the 23 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
18 studies in Diabetes Mellitus, Type 1 by AstraZeneca: none open now, none under way, none of them phase 3. Of 18 finished, 9 (50%) have results posted.
Among the 18 studies in Diabetes Mellitus, Type 1 by AstraZeneca, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 3, and was the 15th registered.
AstraZeneca’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 18 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Placebo tablet orally, once daily for 52 weeks
Other: Placebo for dapagliflozin
Tablets
Tablets
Adjusted Mean Change From Baseline in HbA1c at Week 24
To compare the change from baseline in HbA1c between dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Time frame: Baseline and 24 weeks
Adjusted Mean Percentage Change From Baseline in Total Daily Insulin Dose at Week 24
To compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Time frame: Baseline and 24 weeks
Adjusted Mean Percentage Change From Baseline in Body Weight at Week 24
To compare the percentage change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Time frame: Baseline and 24 weeks
Adjusted Mean Change From Baseline in 24-hour Continuous Glucose Monitoring (CGM) Mean Value at Week 24
To compare the change from baseline in mean value of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Time frame: Baseline and 24 weeks
Adjusted Mean Change From Baseline in 24-hour CGM Mean Amplitude of Glycemic Excursion (MAGE) Value at Week 24
To compare the change from baseline in mean amplitude of glucose excursions (MAGE) of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Time frame: Baseline and 24 weeks
Change From Baseline in the Percent of 24-hour Glucose Readings Obtained From CGM That Falls Within the Target Range of > 70 mg/dL and <= 180 mg/dL (%) at Week 24
To compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of \>70 mg/dL and \<=180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
Time frame: Baseline and 24 weeks
Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24
To compare dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin for the proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit \>=0.5% without severe hypoglycemia events
Time frame: Baseline and 24 weeks
The results on this form are from the 24 week short-term double-blind treatment period. This study was conducted at 148 centers in 13 countries from 8 July 2015 to 2 Sep 2017.
| Milestone | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Started | 271 | 270 | 272 |
| Completed | 244 | 245 | 239 |
| Not completed | 27 | 25 | 33 |
| Withdrew: Adverse event | 17 | 11 | 11 |
| Withdrew: Withdrawal by subject | 5 | 5 | 14 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 1 |
| Withdrew: Discontinued due to dka/hypoglycemia | 2 | 5 | 4 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
To compare the change from baseline in HbA1c between dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
| HbA1c (%) | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Adjusted Mean Change From Baseline in HbA1c at Week 24 | -0.34 (-0.43 to -0.25) | -0.39 (-0.48 to -0.30) | 0.03 (-0.06 to 0.12) |
To compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
| Percentage change | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Adjusted Mean Percentage Change From Baseline in Total Daily Insulin Dose at Week 24 | -8.73 (-11.09 to -6.31) | -9.05 (-11.43 to -6.60) | 2.29 (-0.41 to 5.06) |
To compare the percentage change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
| Percentage change | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Adjusted Mean Percentage Change From Baseline in Body Weight at Week 24 | -3.22 (-3.76 to -2.69) | -3.76 (-4.29 to -3.22) | -0.02 (-0.57 to 0.54) |
To compare the change from baseline in mean value of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
| mg/dL | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Adjusted Mean Change From Baseline in 24-hour Continuous Glucose Monitoring (CGM) Mean Value at Week 24 | -6.46 (-10.04 to -2.87) | -10.54 (-14.14 to -6.94) | 9.20 (5.57 to 12.83) |
To compare the change from baseline in mean amplitude of glucose excursions (MAGE) of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
| mg/dL | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Adjusted Mean Change From Baseline in 24-hour CGM Mean Amplitude of Glycemic Excursion (MAGE) Value at Week 24 | -10.17 (-13.90 to -6.45) | -9.68 (-13.44 to -5.93) | -0.33 (-4.12 to 3.46) |
To compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of \>70 mg/dL and \<=180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment
| % of readings | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Change From Baseline in the Percent of 24-hour Glucose Readings Obtained From CGM That Falls Within the Target Range of > 70 mg/dL and <= 180 mg/dL (%) at Week 24 | 5.92 (4.32 to 7.52) | 7.60 (5.98 to 9.21) | -3.10 (-4.73 to -1.47) |
To compare dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin for the proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit \>=0.5% without severe hypoglycemia events
| Participants | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Number of Responders | 105 | 111 | 54 |
Collected over All adverse events (AEs), including serious adverse events (SAEs), were collected from the time informed consent was signed throughout the treatment period (through week 24).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DAPA 5 MG + INS | 0/271 (0%) | 18/271 (6.6%) | 79/271 (29.2%) |
| DAPA 10 MG + INS | 0/270 (0%) | 7/270 (2.6%) | 77/270 (28.5%) |
| PLA + INS | 0/272 (0%) | 5/272 (1.8%) | 63/272 (23.2%) |
| Event | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 7/271 | 3/270 | 0/272 |
| HypoglycemiaMetabolism and nutrition disorders | 3/271 | 0/270 | 1/272 |
| Hypoglycaemic seizureNervous system disorders | 2/271 | 0/270 | 0/272 |
| Cerebral haemorrhageNervous system disorders | 0/271 | 1/270 | 0/272 |
| ComaNervous system disorders | 0/271 | 1/270 | 0/272 |
| Diabetic hyperglycaemic comaNervous system disorders | 0/271 | 1/270 | 0/272 |
| SeizureNervous system disorders | 0/271 | 1/270 | 0/272 |
| Femur fractureInjury, poisoning and procedural complications | 0/271 | 1/270 | 0/272 |
| Subarachnoid haemorrhageInjury, poisoning and procedural complications | 0/271 | 1/270 | 0/272 |
| Cardiac arrestCardiac disorders | 0/271 | 1/270 | 0/272 |
| Event | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 39/271 | 44/270 | 42/272 |
| PollakiuriaRenal and urinary disorders | 22/271 | 14/270 | 6/272 |
| Upper respiratory tract infectionInfections and infestations | 16/271 | 12/270 | 12/272 |
| HeadacheNervous system disorders | 10/271 | 15/270 | 10/272 |
| ThirstGeneral disorders | 6/271 | 14/270 | 1/272 |
| Age, Continuous(Years) | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS | Total |
|---|---|---|---|---|
| Mean | 42.7 ± 13.35 | 42.4 ± 12.80 | 43.0 ± 13.73 | 42.7 ± 13.29 |
| Sex: Female, Male(Participants) | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS | Total |
|---|---|---|---|---|
| Female | 153 | 149 | 153 | 455 |
| Male | 118 | 121 | 119 | 358 |
| Race/Ethnicity, Customized(Participants) | DAPA 5 MG + INS | DAPA 10 MG + INS | PLA + INS | Total |
|---|---|---|---|---|
| White | 210 | 219 | 208 | 637 |
| Black or African-American | 4 | 7 | 1 | 12 |
| Asian | 57 | 44 | 59 | 160 |
| Other | 0 | 0 | 4 | 4 |
Showing the first 100 of 137 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Sep 2017, 25 months.
Results were first posted in Nov 2018, 1 year 2 months after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 25 months is above that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin